Literature DB >> 3129986

Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response.

P Cabeza Meckert1, J G Chambó, R P Laguens.   

Abstract

Reinfection of chronic chagasic mice after treatment with nifurtimox resulted in different outcomes according to the number of parasites used for inoculation. Nifurtimox-treated chagasic animals injected with 2,500 trypomastigotes developed higher parasitemia and increased mortality compared with nontreated chagasic mice. When reinfection was done with 25 trypomastigotes, treated and nontreated animals showed similar parasitemias and mortalities, which were significantly higher in nonchagasic controls infected for the first time. Immunological studies showed that treatment with nifurtimox led to a decrease in anti-Trypanosoma cruzi antibodies engaged in parasite destruction, inducing either complement-dependent lysis or antibody-dependent cytotoxicity, but no difference in anti-T. cruzi cell-mediated immunity was found between treated and nontreated chagasic animals. It is concluded that treatment with nifurtimox leads to a loss of resistance to reinfection with a large number of trypanosomes, which is maintained with challenge with a few parasites, and that these two thresholds of premunition are probably associated with humoral and cell-mediated anti-T. cruzi immune responses, respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129986      PMCID: PMC172142          DOI: 10.1128/AAC.32.2.241

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Protective immunisation of mice using cell surface glycoprotein from Trypanosoma cruzi.

Authors:  M T Scott; D Snary
Journal:  Nature       Date:  1979-11-01       Impact factor: 49.962

2.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.

Authors:  Z BRENER
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1962 Nov-Dec       Impact factor: 1.846

3.  Antigenic makeup of subcellular fractions of Trypanosoma cruzi.

Authors:  E L Segura; E N Cura; I Paulone; C Vasquez; J A Cerisola
Journal:  J Protozool       Date:  1974-10

4.  Indirect haemagglutination test for Chagas' disease, with a simple method for survey work.

Authors:  R A Neal; R A Miles
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1970 Sep-Oct       Impact factor: 1.846

5.  Trypanosoma cruzi: ability of T-cell-enriched and -depleted lymphocyte populations to passively protect mice.

Authors:  T M Trischmann; B R Bloom
Journal:  Exp Parasitol       Date:  1980-04       Impact factor: 2.011

6.  Effect of specific chemotherapy on the levels of lytic antibodies in Chagas's disease.

Authors:  A U Krettli; J R Cançado; Z Brener
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

7.  Protective immunity and pathology induced by inoculation of mice with different subcellular fractions of Trypanosoma cruzi.

Authors:  A M Ruiz; M Esteva; P Cabeza Meckert; R P Laguens; E L Segura
Journal:  Acta Trop       Date:  1985-12       Impact factor: 3.112

8.  Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox).

Authors:  R Lelchuk; R L Cardoni; A S Fuks
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

9.  Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies.

Authors:  A U Krettli; Z Brener
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

10.  Cell surface glycoproteins of Trypanosoma cruzi: protective immunity in mice and antibody levels in human chagasic sera.

Authors:  D Snary
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

View more
  4 in total

1.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Drug-cured experimental Trypanosoma cruzi infections confer long-lasting and cross-strain protection.

Authors:  Gurdip Singh Mann; Amanda F Francisco; Shiromani Jayawardhana; Martin C Taylor; Michael D Lewis; Francisco Olmo; Elisangela Oliveira de Freitas; Fabiana M S Leoratti; Cesar López-Camacho; Arturo Reyes-Sandoval; John M Kelly
Journal:  PLoS Negl Trop Dis       Date:  2020-04-17

Review 3.  Chagas' disease: an update on immune mechanisms and therapeutic strategies.

Authors:  Silvia Beatriz Boscardin; Ana Claudia Troccoli Torrecilhas; Romina Manarin; Silvia Revelli; Elena Gonzalez Rey; Renata Rosito Tonelli; Ariel Mariano Silber
Journal:  J Cell Mol Med       Date:  2010-01-11       Impact factor: 5.310

4.  Effects of astaxanthin in mice acutely infected with Trypanosoma cruzi.

Authors:  José María Eloy Contreras-Ortiz; Alberto Barbabosa-Pliego; Rigoberto Oros-Pantoja; José Esteban Aparicio-Burgos; José Antonio Zepeda-Escobar; Wael Hegazy Hassan-Moustafa; Laucel Ochoa-García; María Uxúa Alonso-Fresan; Esvieta Tenorio Borroto; Juan Carlos Vázquez-Chagoyán
Journal:  Parasite       Date:  2017-05-31       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.